With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Abstract Disease Overview Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …

Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …

Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …

Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Abstract Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …